AAAAAA

   
Results: 1-13 |
Results: 13
The implication of compromised renal function at presentation in myeloma -Similar outcome in Patients who receive high-dose therapy: A single-centerstudy of 251 previously untreated patients
Authors: Sirohi, B Powles, R Mehta, J Treleaven, J Raje, N Kulkarni, S Rudin, C Bhagwati, N Horton, C Saso, R Singhal, S Parikh, P
Citation: B. Sirohi et al., The implication of compromised renal function at presentation in myeloma -Similar outcome in Patients who receive high-dose therapy: A single-centerstudy of 251 previously untreated patients, MED ONCOL, 18(1), 2001, pp. 39-50
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receivingsequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria
Authors: Sirohi, B Powles, R Kulkarni, S Rudin, C Saso, R Lal, R Singhal, S Mehta, J Horton, C Treleaven, J
Citation: B. Sirohi et al., Comparison of new patients with Bence-Jones, IgG and IgA myeloma receivingsequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria, BONE MAR TR, 28(1), 2001, pp. 29-37
Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience
Authors: Sirohi, B Kulkarni, S Powles, R
Citation: B. Sirohi et al., Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experience, SEM HEMATOL, 38(3), 2001, pp. 209-218
Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma
Authors: Sirohi, B Powles, R Kulkarni, S Rudin, C Saso, R Rigg, A Horton, C Singhal, S Mehta, J Treleaven, J
Citation: B. Sirohi et al., Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma, BR J CANC, 85(3), 2001, pp. 325-332
A low CD34(+) cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34(+) cells/kg be considered the minimum threshold?
Authors: Singhal, S Powles, R Treleaven, J Kulkarni, S Sirohi, B Horton, C Millar, B Shepherd, V Tait, D Saso, R Rowland, A Long, S Mehta, J
Citation: S. Singhal et al., A low CD34(+) cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34(+) cells/kg be considered the minimum threshold?, BONE MAR TR, 26(5), 2000, pp. 489-496
Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients
Authors: Powles, R Sirohi, B Kulkarni, S Bhagwati, N Saso, R Raje, N Horton, C Singhal, S Mehta, J Treleaven, J
Citation: R. Powles et al., Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients, BONE MAR TR, 25(9), 2000, pp. 949-956
Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation
Authors: Singhal, S Powles, R Kulkarni, S Treleaven, J Sirohi, B Millar, B Shepherd, V Saso, R Rowland, A Long, S Cabral, S Horton, C Mehta, J
Citation: S. Singhal et al., Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation, BONE MAR TR, 25(5), 2000, pp. 501-505
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over
Authors: Sirohi, B Powles, R Treleaven, J Mainwaring, P Kulkarni, S Pandha, H Bhagwati, N Horton, C Singhal, S Mehta, J
Citation: B. Sirohi et al., The role of autologous transplantation in patients with multiple myeloma aged 65 years and over, BONE MAR TR, 25(5), 2000, pp. 533-539
Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years
Authors: Kulkarni, S Powles, R Treleaven, J Singhal, S Horton, C Sirohi, B Bhagawati, N Tait, D Saso, R Killick, S Pinkerton, R Atra, A Meller, S Mehta, J
Citation: S. Kulkarni et al., Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years, BONE MAR TR, 25(4), 2000, pp. 365-370
Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial
Authors: Powles, R Mehta, J Kulkarni, S Treleaven, J Millar, B Marsden, J Shepherd, V Rowland, A Sirohi, B Tait, D Horton, C Long, S Singhal, S
Citation: R. Powles et al., Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial, LANCET, 355(9211), 2000, pp. 1231-1237
Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants
Authors: Kulkarni, S Powles, R Treleaven, J Riley, U Singhal, S Horton, C Sirohi, B Bhagwati, N Meller, S Saso, R Mehta, J
Citation: S. Kulkarni et al., Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants, BLOOD, 95(12), 2000, pp. 3683-3686
Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen
Authors: Advani, S Pal, S Venzon, D Adde, M Kurkure, PK Nair, CN Sirohi, B Banavali, SD Hawaldar, R Kolhatkar, BB Vats, T Magrath, I
Citation: S. Advani et al., Acute lymphoblastic leukemia in India: An analysis of prognostic factors using a single treatment regimen, ANN ONCOL, 10(2), 1999, pp. 167-176
Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed diseaseentity with a new staging system
Authors: Sirohi, B Powles, R Mehta, J Raje, N Kulkarni, S Ramiah, V Saso, R Horton, C Bhagwati, N Singhal, S Treleaven, J
Citation: B. Sirohi et al., Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed diseaseentity with a new staging system, BR J HAEM, 107(3), 1999, pp. 656-666
Risultati: 1-13 |